<br>基于间充质干细胞/基质细胞（MSCs）的细胞疗法对炎症性肠病（IBD）治疗的治疗潜力,European Journal of Medical Research

当前位置： X-MOL 学术 › Eur. J. Med. Res. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

基于间充质干细胞/基质细胞（MSCs）的细胞疗法对炎症性肠病（IBD）治疗的治疗潜力
European Journal of Medical Research ( IF 2.8 ) Pub Date : 2023-01-27 , DOI: 10.1186/s40001-023-01008-7
Mohamed J Saadh ₁ , Maria V Mikhailova ₂ , Soheil Rasoolzadegan ₃ , Mojgan Falaki ₄ , Roozbeh Akhavanfar ₅ , José Luis Arias Gonzáles ₆ , Amir Rigi ₇ , Bahman Abedi Kiasari ₈

Affiliation

最近，鉴于其免疫调节和促生存属性，间充质干细胞/基质细胞（MSCs）疗法已成为治疗炎症性肠病（IBD）的新兴治疗方式。MSC 通过分泌多种抗炎介质来缓解失调的炎症反应，例如白细胞介素 10 （IL-10）、转化生长因子-β （TGFβ）、前列腺素 E2 （PGE2）、肿瘤坏死因子刺激基因 6 （TSG-6）等。事实上，IBD 的 MSC 治疗主要通过局部微循环构建、定植和修复以及免疫调节进行，从而减轻疾病的严重程度。临床治疗效果取决于活的 MSC 通过旁分泌机制显着分泌各种分泌分子，这些机制是肠道免疫微生物群调节以及肠上皮细胞（IEC）和肠道干细胞（ISC）等周围细胞的增殖和分化所必需的。例如，MSC 可以诱导 IECs 增殖并上调紧密连接（TJ）相关蛋白的表达，从而确保肠道屏障的完整性。关于动物研究得出的令人鼓舞的结果，正在进行或正在进行各种临床试验，以解决 MSCs 在 IBD 患者中给药的安全性和有效性。尽管 MSCs 给药的安全性和短期疗效已得到证实，但 MSCs 移植的长期疗效尚未得到验证。在此，我们强调了 MSCs 疗法的治疗能力，包括初始 MSCs、预处理 MSCs，以及 MSCs 衍生的外泌体，以减轻实验模型中 IBD 的严重程度。此外，还提供了已发表的 IBD 患者临床试验的简要概述。

"点击查看英文标题和摘要"

Therapeutic potential of mesenchymal stem/stromal cells (MSCs)-based cell therapy for inflammatory bowel diseases (IBD) therapy

Recently, mesenchymal stem/stromal cells (MSCs) therapy has become an emerging therapeutic modality for the treatment of inflammatory bowel disease (IBD), given their immunoregulatory and pro-survival attributes. MSCs alleviate dysregulated inflammatory responses through the secretion of a myriad of anti-inflammatory mediators, such as interleukin 10 (IL-10), transforming growth factor-β (TGFβ), prostaglandin E2 (PGE2), tumor necrosis factor-stimulated gene-6 (TSG-6), etc. Indeed, MSC treatment of IBD is largely carried out through local microcirculation construction, colonization and repair, and immunomodulation, thus alleviating diseases severity. The clinical therapeutic efficacy relies on to the marked secretion of various secretory molecules from viable MSCs via paracrine mechanisms that are required for gut immuno-microbiota regulation and the proliferation and differentiation of surrounding cells like intestinal epithelial cells (IECs) and intestinal stem cells (ISCs). For example, MSCs can induce IECs proliferation and upregulate the expression of tight junction (TJs)-associated protein, ensuring intestinal barrier integrity. Concerning the encouraging results derived from animal studies, various clinical trials are conducted or ongoing to address the safety and efficacy of MSCs administration in IBD patients. Although the safety and short-term efficacy of MSCs administration have been evinced, the long-term efficacy of MSCs transplantation has not yet been verified. Herein, we have emphasized the illumination of the therapeutic capacity of MSCs therapy, including naïve MSCs, preconditioned MSCs, and also MSCs-derived exosomes, to alleviate IBD severity in experimental models. Also, a brief overview of published clinical trials in IBD patients has been delivered.

更新日期：2023-01-27

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文本刊介绍/投稿指南